NCT00134173

A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease

Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,100 (planned)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To look at ultrasound images taken in the blood vessels of the heart and to look at various lipids in the blood of people with known coronary heart disease

Detailed description

For additional information please call: 1-800-718-1021

Conditions

• Coronary Disease
• Coronary Arteriosclerosis
• Hyperlipidemia

Interventions

Type	Name	Description
DRUG	torcetrapib/atorvastatin
DRUG	atorvastatin

Timeline

• Start date: 2003-10-01
• Completion: 2006-09-01
• First posted: 2005-08-24
• Last updated: 2007-12-10

Locations

146 sites across 6 countries: United States, Belgium, Canada, Netherlands, Poland, Spain